A recent review demonstrated that sodium–glucose cotransporter 2 inhibitors (SGLT2is) have the ability to reduce the risk of dementia by remodeling glucotoxicity or reducing hyperphosphorylated tau levels and amyloid β accumulation in the brain; however, other studies on this subject had inconclusive results [30]. This evidence concerns the gene MAPT and dementia.